Heart Failure Society of America (HFSA 2026) 9 - 12 October 2026

Inflammatory biomarkers in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with coramitug: post hoc analysis of a phase 2 randomized trial

Authors :

Nowell M Fine¹,²; Wansuk Choi³; Nelson Ferreira⁴; Bjarke Follin⁴; Marianna Fontana⁵; Mathew S Maurer⁶; Uzoma Obiaka³; Julie L Rosenthal⁷; Peter-Paul Zwetsloot⁸,⁹; Kenichi Tsujita¹⁰

Affiliations

View Details Hide Details

Download the poster (.pdf)

Keywords

Cardiovascular Disease

Congress poster

Anti-TTR monoclonal antibody

Coramitug

PHASE 2 (RCT)

Search Science Hub

Are you a healthcare professional?

Inflammatory biomarkers in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with coramitug: post hoc analysis of a phase 2 randomized trial